18889881171
Kalkine 0
countryflagUS

Allarity Therapeutics Inc

Healthcare US ALLR

0.9965USD
0.01(1.34%)

Last update at 2025-07-08T17:12:00Z

Day Range

0.971.00
LowHigh

52 Week Range

1.00378.00
LowHigh

Fundamentals

  • Previous Close 0.98
  • Market Cap2.06M
  • Volume78386
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-16.89500M
  • Revenue TTM-7.12700M
  • Revenue Per Share TTM-0.018
  • Gross Profit TTM -36.34800M
  • Diluted EPS TTM-10.98

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -17.57900M -26.51500M -7.23400M -18.97700M -
Minority interest - 0.00000M 0.01M 0.09M -
Net income -16.05800M -26.64800M -5.07300M -14.40000M -
Selling general administrative 9.96M 12.36M 4.10M 3.87M -
Selling and marketing expenses - - - - -
Gross profit - - - 0.12M -
Reconciled depreciation 0.06M 0.11M 0.05M 0.05M -
Ebit -34.46300M -26.55600M -9.22700M -17.61100M -32.13400M
Ebitda -16.80200M -28.27100M -9.86200M -10.05900M -
Depreciation and amortization 17.66M -1.71500M -0.63500M 7.55M -
Non operating income net other 16.88M - - - -
Operating income -34.46300M -26.55600M -9.22700M -17.61100M -
Other operating expenses 16.89M 26.56M 9.23M 10.24M -
Interest expense 0.22M 0.50M 0.23M 3.31M 0.00000M
Tax provision -1.52100M 0.13M -2.16100M -4.57700M -
Interest income 0.03M - 0.00000M 0.00700M -
Net interest income -0.19300M -1.84600M -0.22700M -3.30500M -
Extraordinary items - - - - -
Non recurring 17.57M - - - -
Other items - - - - -
Income tax expense -1.52100M 0.13M -2.16100M -4.57700M -6.97300M
Total revenue 0.00000M 0.00000M 0.00000M 0.12M -
Total operating expenses 16.89M 26.56M 9.23M 10.24M -
Cost of revenue - - - - -
Total other income expense net 16.88M 0.04M 1.99M -1.36600M -
Discontinued operations - - - - -
Net income from continuing ops -16.05800M -26.64800M -5.07300M -14.40000M -
Net income applicable to common shares -21.05100M -26.64800M -47.60800M -131.95500M -14.93900M
Preferred stock and other adjustments 4.99M - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 11.86M 14.54M 49.63M 33.40M 31.61M
Intangible assets 9.87M 9.55M 28.14M 30.49M 27.69M
Earning assets - - - - -
Other current assets 0.86M 2.07M 1.50M 0.29M 0.16M
Total liab 14.61M 12.65M 30.85M 6.55M 10.70M
Total stockholder equity -2.75100M 1.89M 18.78M 26.85M 18.09M
Deferred long term liab - 1.43M - - -
Other current liab 4.39M 2.32M 11.27M 1.90M 1.92M
Common stock - 0.00200M 0.81M 1.62M 0.92M
Capital stock 1.74M 2.00M 1.44M 1.62M 0.92M
Retained earnings -94.45100M -82.55000M -66.49200M -37.43200M -32.37400M
Other liab - 0.35M 9.14M 2.28M 6.10M
Good will - - - - -
Other assets - - - - -
Cash 0.17M 2.03M 19.55M 0.30M 1.52M
Cash and equivalents - - - - -
Total current liabilities 14.17M 11.22M 20.72M 5.53M 4.72M
Current deferred revenue 0.06M - 8.65M - -
Net debt 1.13M 1.71M -18.46900M 1.49M -0.56100M
Short term debt 1.30M 2.65M 0.10M 1.52M 0.62M
Short long term debt 1.30M 2.64M - 1.41M 0.54M
Short long term debt total 1.30M 3.73M 1.09M 1.79M 0.96M
Other stockholder equity 90.37M 83.16M 84.43M 61.28M 50.62M
Property plant equipment - 0.02M 0.09M 2.13M 2.92M
Total current assets 1.97M 4.97M 21.05M 1.72M 3.34M
Long term investments - - 0.35M 0.84M 0.14M
Net tangible assets - -7.65900M -9.98300M -15.13700M -32.11400M
Short term investments - 0.00000M - - -
Net receivables 0.95M 0.87M 1.34M 1.12M 1.66M
Long term debt - 1.08M 0.98M - -
Inventory - - -1.34500M - -
Accounts payable 8.42M 6.25M 0.70M 2.12M 2.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.41100M -0.72100M -0.60000M 1.38M -1.08600M
Additional paid in capital - - - - -
Common stock total equity - 0.00200M - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -82.55000M - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.00600M 0.35M - -
Deferred long term asset charges - - - - -
Non current assets total 9.89M 9.58M 28.58M 31.69M 28.26M
Capital lease obligations 0.00000M 0.00800M 0.11M 0.38M 0.43M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.79M 1.00M -0.00300M 1.55M 11.38M
Change to liabilities 1.37M -1.31100M -1.72000M 1.58M -3.18300M
Total cashflows from investing activities 0.79M 1.00M -0.01900M -3.81400M 9.86M
Net borrowings 1.00M 0.97M 17.73M 22.05M 18.89M
Total cash from financing activities -1.31100M 33.82M 6.03M 11.20M 15.79M
Change to operating activities -6.51600M 6.87M 0.94M 8.78M -0.06800M
Net income -16.05800M -26.64800M -5.07300M -14.40000M -14.93900M
Change in cash -17.52600M 19.26M -1.22600M 1.29M -1.77900M
Begin period cash flow 19.55M 0.30M 1.52M 0.24M -
End period cash flow 2.03M 19.55M 0.30M 1.52M 0.24M
Total cash from operating activities -16.81700M -15.05000M -7.25100M -10.11300M -27.62400M
Issuance of capital stock 0.00000M 32.12M 3.70M 13.56M -
Depreciation 0.06M 0.11M 0.05M 0.05M 0.21M
Other cashflows from investing activities 0.81M - - - -
Dividends paid 1.51M - - - -
Change to inventory - - - 1.97M 1.05M
Change to account receivables - 0.00000M 0.10M -0.09500M 0.83M
Sale purchase of stock -1.51100M - - - -
Other cashflows from financing activities 0.20M 4.64M 2.86M 2.75M -3.29900M
Change to netincome 16.52M 5.92M -4.43000M 48.72M -11.52700M
Capital expenditures 0.02M 0.02M 0.00300M 0.00800M 0.04M
Change receivables - - - - -
Cash flows other operating -18.70500M - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -17.33700M - - - -
Change in working capital -0.32800M 5.57M 0.45M 2.06M -
Stock based compensation 1.75M 6.37M 0.62M 0.33M -
Other non cash items -0.63100M -0.46600M -1.99900M 5.60M -
Free cash flow -16.83500M -15.05000M -7.25400M -10.12100M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ALLR
Allarity Therapeutics Inc		 0.01 1.34% 1.00 - - - 0.38 -0.0842
NVO
Novo Nordisk A/S		 -0.5201 0.75% 68.80 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 70.12 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 10.38 2.26% 469.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 18.29 3.40% 556.40 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Allarity Therapeutics Inc

24 School Street, Boston, MA, United States, 02108

Key Executives

Name Title Year Born
Mr. James G. Cullem J.D. Interim CEO, Chief Bus. Officer, Sr. VP of Corp. Devel. & Director 1969
Dr. Marie Foegh DrSc, M.D. Chief Medical Officer 1944
Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D. Co-Founder 1955
Dr. Steen Meier Knudsen Ph.D. Founder & Chief Scientific Officer 1961
Mr. Thomas H. Jensen Founder, Sr. VP of Investor Relations & Director 1978
Mr. Claus Frisenberg Pedersen Chief Commercial Officer 1972
Ms. Joan Brown Interim CFO & Director of Financial Reporting 1953
Ms. Annie Rasmussen Chief of Clinical Operations 1957
Mr. Thomas H. Jensen Founder, CEO, Senior VP of Investor Relations & Director 1978
Ms. Joan Y. Brown Interim CFO 1954

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.